HPVAC
GBC-HpVac focuses on the development of GBC-R1 as a preventive and therapeutic first-line therapy for asthma and related allergic diseases. GBC-HpVac holds an exclusive, worldwide license from the University of Zurich. GBC-HpVac was founded in 2016 and is headquartered in Geneva, Switzerland.
HPVAC
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2016-06-01
Address:
Geneva, Geneve, Switzerland
Country:
Switzerland
Website Url:
http://www.gbc-hpvac.com
Total Employee:
1+
Status:
Active
Contact:
+41 22 794 40 20
Email Addresses:
[email protected]
Total Funding:
2.41 M USD
Technology used in webpage:
IPv6 Infomaniak Network
Current Advisors List
